Get the Stockscreener App
1.36
0.00%
0.00
After Hours:
1.34
-0.02
-1.47%
Quince Therapeutics Inc stock is traded at $1.36, with a volume of 1.13M.
It is up +0.00% in the last 24 hours and up +46.08% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$1.36
Open:
$1.37
24h Volume:
1.13M
Relative Volume:
0.12
Market Cap:
$22.17M
Revenue:
-
Net Income/Loss:
$-83.98M
P/E Ratio:
-0.1019
EPS:
-13.3519
Net Cash Flow:
$-41.78M
1W Performance:
-0.73%
1M Performance:
+46.08%
6M Performance:
-92.27%
1Y Performance:
-87.91%
1-Day Range:
$1.31
$1.37
1-Week Range:
$1.231
$1.53
52-Week Range:
$0.80
$45.50
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.36 | 22.17M | 0 | -83.98M | -41.78M | -13.35 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Why did QNCX stock plummet over 90% today? - MSN
Quince Therapeutics Appoints June Bray to Board - The Globe and Mail
Quince Therapeutics settles $16.4M debt with $5.5M payment - MSN
Quince Therapeutics appoints June Bray to board of directors - Investing.com
Quince Therapeutics appoints June Bray to board of directors By Investing.com - Investing.com UK
[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics (QNCX) Stock: Worth Entering? (-6.93%) 2026-04-20Top Breakouts - Cổng thông tin điện tử Tỉnh Sơn La
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Quince Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Earnings Beat: Should I hold or sell Quince Therapeutics Inc now2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Treasury Yields: Whats Quince Therapeutics Incs historical returnMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Opening: Can Quince Therapeutics Inc sustain its profitabilityM&A Rumor & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Quince Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
QNCX: Lead asset failed in Phase 3, triggering strategic review and raising going concern risks - TradingView
Phase 3 miss leaves Quince Therapeutics (QNCX) chasing reverse merger path - Stock Titan
Quince Therapeutics Announces 1-for-10 Reverse Stock Split - The Globe and Mail
Quince Therapeutics To Carry Out 1-for-10 Reverse Stock Split On April 13th, 2026 - Moomoo
Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday - Investing.com Australia
Quince Therapeutics, Inc. Files Form 8-K Announcing Certificate of Amendment and Company Details - Minichart
Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday By Investing.com - Investing.com South Africa
Quince Therapeutics (QNCX) enacts 1-for-10 reverse split, 16.3M shares post-split - Stock Titan
Dow Jumps Over 1,300 Points; Delta Air Lines Shares Gain After Q1 Results - Sahm
US Market Preview | OMEX Up 148%; Iran CeasefireStocks, Gold Rally, Oil Dives; SpaceX-Tesla Merger Buzz Grows; DAL Surges 12% After Earnings - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
History Review: Is Quince Therapeutics Inc stock overvalued or fairly pricedEarnings Recap Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
$Quince Therapeutics (QNCX.US)$ thanks 🤑🤑🤑 - Moomoo
$Quince Therapeutics (QNCX.US)$ goodluck guy - Moomoo
$Quince Therapeutics (QNCX.US)$ mon stop fight it - Moomoo
$Quince Therapeutics (QNCX.US)$ thank clear - Moomoo
$Quince Therapeutics (QNCX.US)$ awwww - Moomoo
$Quince Therapeutics (QNCX.US)$ - Moomoo
$Quince Therapeutics (QNCX.US)$ i just sold off my initial investment - Moomoo
Plays for 4-08-2026 $BTC Digital (BTCT.US)$ $Quince Therapeutics (QNCX.US)$ - Moomoo
still holding - Moomoo
Trending Stocks Today | U Power Surges 59.06% Post-Market - Moomoo
Wondering what's happening in today's after-hours session? - ChartMill
QNCX PE Ratio & Valuation, Is QNCX Overvalued - Intellectia AI
Quince Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView — Track All Markets
QNCX Stock Analysis: Quince Therapeutics Inc. 3.23% drop to $0.1, biotech performance assessment - UBND thành phố Hải Phòng
Will Quince Therapeutics (QNCX) Stock Miss Expectations | Price at $0.99, Down 3.23%Shared Buy Zones - UBND thành phố Hải Phòng
Quince Therapeutics Delays Annual 10-K Filing - TipRanks
Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension - Stock Titan
QNCX Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Aug Setups: Will Quince Therapeutics Inc benefit from AI trends2026 Earnings & Fast Moving Trade Plans - baoquankhu1.vn
Quince Therapeutics settles $16.4M debt for $5.5M payment By Investing.com - Investing.com South Africa
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):